Literature DB >> 12551977

Mucosal priming of simian immunodeficiency virus-specific cytotoxic T-lymphocyte responses in rhesus macaques by the Salmonella type III secretion antigen delivery system.

David T Evans1, Li-Mei Chen, Jacqueline Gillis, Kuei-Chin Lin, Brian Harty, Gail P Mazzara, Ruben O Donis, Keith G Mansfield, Jeffrey D Lifson, Ronald C Desrosiers, Jorge E Galán, R Paul Johnson.   

Abstract

Nearly all human immunodeficiency virus (HIV) infections are acquired mucosally, and the gut-associated lymphoid tissues are important sites for early virus replication. Thus, vaccine strategies designed to prime virus-specific cytotoxic T lymphocyte (CTL) responses that home to mucosal compartments may be particularly effective at preventing or containing HIV infection. The Salmonella type III secretion system has been shown to be an effective approach for stimulating mucosal CTL responses in mice. We therefore tested DeltaphoP-phoQ attenuated strains of Salmonella enterica serovar Typhimurium and S. enterica serovar Typhi expressing fragments of the simian immunodeficiency virus (SIV) Gag protein fused to the type III-secreted SopE protein for the ability to prime virus-specific CTL responses in rhesus macaques. Mamu-A*01(+) macaques were inoculated with three oral doses of recombinant Salmonella, followed by a peripheral boost with modified vaccinia virus Ankara expressing SIV Gag (MVA Gag). Transient low-level CTL responses to the Mamu-A*01 Gag(181-189) epitope were detected following each dose of Salmonella. After boosting with MVA Gag, strong Gag-specific CTL responses were consistently detected, and tetramer staining revealed the expansion of Gag(181-189)-specific CD8(+) T-cell responses in peripheral blood. A significant percentage of the Gag(181-189)-specific T-cell population in each animal also expressed the intestinal homing receptor alpha4beta7. Additionally, Gag(181-189)-specific CD8(+) T cells were detected in lymphocytes isolated from the colon. Yet, despite these responses, Salmonella-primed/MVA-boosted animals did not exhibit improved control of virus replication following a rectal challenge with SIVmac239. Nevertheless, this study demonstrates the potential of mucosal priming by the Salmonella type III secretion system to direct SIV-specific cellular immune responses to the gastrointestinal mucosa in a primate model.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12551977      PMCID: PMC141091          DOI: 10.1128/jvi.77.4.2400-2409.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen.

Authors:  T M Allen; T U Vogel; D H Fuller; B R Mothé; S Steffen; J E Boyson; T Shipley; J Fuller; T Hanke; A Sette; J D Altman; B Moss; A J McMichael; D I Watkins
Journal:  J Immunol       Date:  2000-05-01       Impact factor: 5.422

2.  Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination.

Authors:  D H Barouch; S Santra; J E Schmitz; M J Kuroda; T M Fu; W Wagner; M Bilska; A Craiu; X X Zheng; G R Krivulka; K Beaudry; M A Lifton; C E Nickerson; W L Trigona; K Punt; D C Freed; L Guan; S Dubey; D Casimiro; A Simon; M E Davies; M Chastain; T B Strom; R S Gelman; D C Montefiori; M G Lewis; E A Emini; J W Shiver; N L Letvin
Journal:  Science       Date:  2000-10-20       Impact factor: 47.728

3.  An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants.

Authors:  N F Rose; P A Marx; A Luckay; D F Nixon; W J Moretto; S M Donahoe; D Montefiori; A Roberts; L Buonocore; J K Rose
Journal:  Cell       Date:  2001-09-07       Impact factor: 41.582

4.  Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

Authors:  R R Amara; F Villinger; J D Altman; S L Lydy; S P O'Neil; S I Staprans; D C Montefiori; Y Xu; J G Herndon; L S Wyatt; M A Candido; N L Kozyr; P L Earl; J M Smith; H L Ma; B D Grimm; M L Hulsey; J Miller; H M McClure; J M McNicholl; B Moss; H L Robinson
Journal:  Science       Date:  2001-04-06       Impact factor: 47.728

5.  Prime-boost immunization with DNA vaccine: mucosal route of administration changes the rules.

Authors:  S K Eo; M Gierynska; A A Kamar; B T Rouse
Journal:  J Immunol       Date:  2001-05-01       Impact factor: 5.422

6.  Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus.

Authors:  C G Murphy; W T Lucas; R E Means; S Czajak; C L Hale; J D Lifson; A Kaur; R P Johnson; D M Knipe; R C Desrosiers
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

7.  Identifying the target cell in primary simian immunodeficiency virus (SIV) infection: highly activated memory CD4(+) T cells are rapidly eliminated in early SIV infection in vivo.

Authors:  R S Veazey; I C Tham; K G Mansfield; M DeMaria; A E Forand; D E Shvetz; L V Chalifoux; P K Sehgal; A A Lackner
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

8.  Immunization with live attenuated simian immunodeficiency virus induces strong type 1 T helper responses and beta-chemokine production.

Authors:  M C Gauduin; R L Glickman; S Ahmad; T Yilma; R P Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

9.  Induction of mucosal homing virus-specific CD8(+) T lymphocytes by attenuated simian immunodeficiency virus.

Authors:  M A Cromwell; R S Veazey; J D Altman; K G Mansfield; R Glickman; T M Allen; D I Watkins; A A Lackner; R P Johnson
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

10.  Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment.

Authors:  J D Lifson; J L Rossio; M Piatak; T Parks; L Li; R Kiser; V Coalter; B Fisher; B M Flynn; S Czajak; V M Hirsch; K A Reimann; J E Schmitz; J Ghrayeb; N Bischofberger; M A Nowak; R C Desrosiers; D Wodarz
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

View more
  48 in total

1.  Long-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization.

Authors:  Vainav Patel; Antonio Valentin; Viraj Kulkarni; Margherita Rosati; Cristina Bergamaschi; Rashmi Jalah; Candido Alicea; Jacob T Minang; Matthew T Trivett; Claes Ohlen; Jun Zhao; Marjorie Robert-Guroff; Amir S Khan; Ruxandra Draghia-Akli; Barbara K Felber; George N Pavlakis
Journal:  Vaccine       Date:  2010-05-06       Impact factor: 3.641

2.  Live attenuated Salmonella vaccines against Mycobacterium tuberculosis with antigen delivery via the type III secretion system.

Authors:  María Dolores Juárez-Rodríguez; Lourdes T Arteaga-Cortés; Rebin Kader; Roy Curtiss; Josephine E Clark-Curtiss
Journal:  Infect Immun       Date:  2011-12-05       Impact factor: 3.441

Review 3.  Enteric pathogens as vaccine vectors for foreign antigen delivery.

Authors:  Camille N Kotton; Elizabeth L Hohmann
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

4.  Ability of herpes simplex virus vectors to boost immune responses to DNA vectors and to protect against challenge by simian immunodeficiency virus.

Authors:  Amitinder Kaur; Hannah B Sanford; Deirdre Garry; Sabine Lang; Sherry A Klumpp; Daisuke Watanabe; Roderick T Bronson; Jeffrey D Lifson; Margherita Rosati; George N Pavlakis; Barbara K Felber; David M Knipe; Ronald C Desrosiers
Journal:  Virology       Date:  2006-09-07       Impact factor: 3.616

5.  Optimization of the delivery of heterologous proteins by the Salmonella enterica serovar Typhimurium type III secretion system for vaccine development.

Authors:  Li-Mei Chen; Gabriel Briones; Ruben O Donis; Jorge E Galán
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

6.  In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines.

Authors:  Hiroyoshi Nishikawa; Eiichi Sato; Gabriel Briones; Li-Mei Chen; Mitsutoshi Matsuo; Yasuhiro Nagata; Gerd Ritter; Elke Jäger; Hideki Nomura; Shigeto Kondo; Isao Tawara; Takuma Kato; Hiroshi Shiku; Lloyd J Old; Jorge E Galán; Sacha Gnjatic
Journal:  J Clin Invest       Date:  2006-06-22       Impact factor: 14.808

Review 7.  Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business".

Authors:  Kimberly A Schoenly; David B Weiner
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

Review 8.  Bacterial vectors for active immunotherapy reach clinical and industrial stages.

Authors:  Audrey Le Gouëllec; Xavier Chauchet; Benoit Polack; Laurent Buffat; Bertrand Toussaint
Journal:  Hum Vaccin Immunother       Date:  2012-08-16       Impact factor: 3.452

9.  Immunogenicity of recombinant attenuated Salmonella enterica serovar Typhimurium vaccine strains carrying a gene that encodes Eimeria tenella antigen SO7.

Authors:  Vjollca Konjufca; Mark Jenkins; Shifeng Wang; Maria Dolores Juarez-Rodriguez; Roy Curtiss
Journal:  Infect Immun       Date:  2008-09-22       Impact factor: 3.441

10.  A safe bacterial microsyringe for in vivo antigen delivery and immunotherapy.

Authors:  Audrey Le Gouëllec; Xavier Chauchet; David Laurin; Caroline Aspord; Julien Verove; Yan Wang; Charlotte Genestet; Candice Trocme; Mitra Ahmadi; Sandrine Martin; Alexis Broisat; François Cretin; Catherine Ghezzi; Benoit Polack; Joël Plumas; Bertrand Toussaint
Journal:  Mol Ther       Date:  2013-03-26       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.